CLNN - clene.com Debt to Book Capitalization Ratio

Brandmark of clene.com (CLNN)

The speculative potential of Clene Inc. (CLNN) relies on its patented ALS therapy platform, although liquidity shortages and regulatory risks pose a threat of bankruptcy. This debt-to-equity structure chart on GURU.Markets reflects current dynamics, where the indicator remains at 0.00. Growth prospects are based on the low-cost physicochemical synthesis of nanocrystalline drugs, which will ensure high scalability upon FDA approval.

Clene (CLNN) - Debts to Book Value from 07/04/2022 to 10/27/2026
Original product of clene.com

This indicator is calculated as the ratio of total liabilities to equity, reflecting the business's degree of dependence on borrowed funds. The metric determines financial stability and bankruptcy risk in the event of asset depreciation. The Clene Inc. (CLNN) outsourcing model minimizes capital expenditures on production by passing operating costs onto contractors. This directly impacts the ratio of the company's total debt to book equity. The trend of this indicator demonstrates the efficiency of leverage management.

Competitors of Clene Inc.

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|Debts to Book Capitalization VKTX|Debt to Book Value SUPN|Debt to Book Capitalization Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|Debt to Book Capitalization Ratio Denali (DNLI)|HRMY: Debts to Book Capitalization|Biohaven Corp - Debts to Book Value|Amylyx Pharmaceuticals (AMLX) - Debt to Book Capitalization Ratio|TRVI - Debt to Book Value Ratio|Debts to Book Capitalization PRAX|Debts to Book Value Anavex|CBLL - Debt to Book Value|Debt to Net Assets Ratio prothena.com|ALEC (Alector, Inc.) - Debts to Book Capitalization|Debts to Net Assets ANNX (annexonbio.com)|OMER - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Neurogene Inc NGNE|ACIU: Debts to Book Capitalization|Voyager Corp (VYGR) - Debt to Book Value|Neumora Therapeutics - Debt to Book Value|scilexholding.com (SCLX) - Debts to Net Assets|Debts to Book Capitalization TVGN|Debt to Book Value ACOG|Debt to Book Capitalization Ratio Cognition Therapeutics (CGTX)|Debt to Book Capitalization Ratio IKT (Inhibikase Pharma)|SAVA - Debt to Book Capitalization Ratio|Assertio Holdings - Debt to Book Value Ratio|Coya (COYA) - Debt to Book Capitalization Ratio|VTGN: Debt to Book Value Ratio|Debt to Book Capitalization Ratio ovidrx.com|Acumen Pharmaceuticals, Inc (ABOS) - Debt to Book Value Ratio|Debts to Book Capitalization CRVO (CervoMed Inc.)|Debts to Book Value Alterity Therapeutics Ltd (ATHE)|Debt to Book Value PEPG|Debts to Book Capitalization JUNS (Jupiter Neurosciences, Inc.)|Debt to Book Capitalization Ratio Relmada|Annovis Bio Corporation - Debt to Net Assets Ratio|GRCE (Grace Tx) - Debt to Book Capitalization Ratio|AIFF - Debts to Book Value|KLTO (anewmeds.com) - Debts to Book Capitalization|NRSN (NeuroSense Therapeutics Ltd.) - Debt to Book Value|Debt to Book Capitalization Ratio Reviva Pharmaceuticals Holdings|Debt to Book Capitalization Ratio MetaVia, Inc.|NeurAxis, Inc. - Debts to Book Capitalization|Debts to Book Value HSDT (heliusmedical.com)|PASG - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Neuphoria Therapeutics, Inc. NEUP|NERV (Minerva Neurosciences Corp) - Debts to Book Capitalization|Athira Pharma Corp (ATHA) - Debts to Book Value|Debt to Book Value Addex Therapeutics ADXN|Alzamend Neuro (ALZN) - Debt to Net Assets Ratio|CYCN: Debts to Book Capitalization|Debts to Net Assets PTIX|Debt to Book Capitalization Ratio Pasithea Therapeutics KTTA|Debt to Book Value Ratio cortigent.com (CRGT)|Avenue Therapeutics - Debts to Book Capitalization|BCLI - Debt to Book Value|Debt to Book Value CARA (Cara Therapeutics)|CHRO - Debts to Net Assets|ELYM (eliemtx.com) - Debts to Book Capitalization|ITCI (Intra-Cellular Therapies, Inc.) - Debt to Book Value|Debt to Book Capitalization Ratio Longboard Pharmaceuticals|Debt to Book Capitalization Ratio MRNS|Debt to Book Capitalization Ratio NKGen Biotech NKGN|Debt to Book Value Ratio NRBO (NeuroBo Pharmaceuticals Inc)|SAGE - Debt to Book Capitalization Ratio|Synaptogenix, Inc - Debt to Book Value Ratio|Trevena, Inc. (TRVN) - Debt to Book Capitalization Ratio|VIGL - Debt to Book Value Ratio|Debts to Book Capitalization WENA|Debts to Book Value Cerevel Therapeutics Inc